Skip to main content
SpringerLink
Log in

Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy

  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

There is a high risk of developing neutralizing and non-neutralizing antibodies when GM-CSF is used as an immunomodulatory agent in non-immune compromised patients and not in combination with chemotherapy. The presence of neutralizing antibodies may seriously hamper the clinical response of the patients This must be taken into account when designing protocols if the biologic activity of the exogenously administered GM-CSF is not to be impaired and the endogenous production of GM-CSF is not to be inactivated. Assessment of production of neutralising antibodies during cytokine therapy is important for predicting the clinical response to progressive therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ratain, M., Golomb, H., Vardiman, J., Yokes, E., Jacobs, R. and Daly, K. (1985) Treatment of hairy cell leukemia with recombinant alpha2 interferon.Blood 65, 644.

    PubMed  CAS  Google Scholar 

  2. Huber, C, Flener, R. and Gastl, G. (1985) Interferon-alpha- 2C in the treatment of hairy cell leukemia.Oncology 42 (suppl 1), 7.

    Article  PubMed  Google Scholar 

  3. Foon, K., Maluish, A. and Abrams, P. (1986) Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia: therapeutic and immunologic results.Am. J. Med. 80, 351.

    Article  PubMed  CAS  Google Scholar 

  4. Steis, R.G., Smith, J.W., Urba, W.J., Clark, J.W., Irri, L.M., Evans, L.M., Schoenberger, C. and Longo, D.L. (1988) Resistance to recombinant interferon alfa-2a in hairy-cell leukaemia associated with neutralizing anti-interferon antibodies.N. Engl. J. Med. 318, 1409.

    Article  PubMed  CAS  Google Scholar 

  5. Steis, R. and Longo, D. (1994) Clinical relevance of recombinant interferon-u2 antibodies in patients with hairy cell leukemia.J. Interferon Res. 14, 207.

    PubMed  CAS  Google Scholar 

  6. Antonelli, G., Giannelli, G., Pistello, M., Maggi, F., Vatterom, L., Currenti, M., Del Vecchio, S., Roffi, L., Pastore, G. and Dianzani, F. (1994) Clinical significanceof recombinant interferon-α2 neutralizing antibodies in hepatitis patients.J. Interferon. Res. 14, 211.

    PubMed  CAS  Google Scholar 

  7. Oberg, K. (1994) Autoimmunity and antibodies to interferons in patients with carcinoid tumors: clinical consequences.J. Interferon Res. 14, 215.

    PubMed  CAS  Google Scholar 

  8. Antonelli, G., Currenti, M., Turriziani, O. and Dianzani, F. 1991) Neutralizing antibodies to interferon-a: relative frequency in patients treated with different interferon preparations.J. Infect. Dis. 163, 882.

    PubMed  CAS  Google Scholar 

  9. Rönnblom, L., Tiensuujanson, E. and Peters, A. (1992) Characterization of anti-interferon-a antibodies appearing during recombinant interferon-α2a treatment.Clin. Exp. Immunol. 89, 330.

    PubMed  Google Scholar 

  10. Galton, J.E., Bedford, P. and Scott, J.E. (1989) Antibodies to lymphoblastoid interferon.Lancet ii, 572.

    Article  Google Scholar 

  11. Ragnhammar, P., Friesen, H.-J., Frödin, J.-E., Lefvert, A. K., Hassan, M., Österborg, A. and Mellstedt, H. (1994) Induction of anti-recombinant human granulocyte-macro- phage colony-stimulating factor(Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients.Blood 84, 4078.

    PubMed  CAS  Google Scholar 

  12. Dorr, R.T. (1993) Clinical properties of yeast-derived versusEscherichia coli-derived granulocyte-macrophage colony-stimulating factor.Clinical Therapeutics 15, 19.

    PubMed  CAS  Google Scholar 

  13. Wong, G.C., Witeck, J.S. and Temple, P.A. (1985) Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins.Science 228, 810.

    Article  PubMed  CAS  Google Scholar 

  14. Canrrell, M.A., Anderson, D. and Cerretti, D.P. (1985) Cloning, sequence and expression of a human granulocyte macrophage colony stimulating factor.Proc. Natl. Acad. Sci. 82, 6250.

    Article  Google Scholar 

  15. Burgess, A.W., Begley, CG., Johnson, G.R., Lopez, A.F., Williamson, DJ., Mermod, J.J., Simpson, R.J., Schmitz, A. and DeLamarter, J.F. (1987) Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor.Blood 69, 43.

    PubMed  CAS  Google Scholar 

  16. Gamble, J.R., Elliott, M.J., Jaipargas, E., Lopez, A.F. and Vadas, M.A. (1989) Regulation of human monocyte adherence by granulocyte-macrophage colony-stimulating factor.Proc. Natl. Acad. Sci. USA 86, 7169.

    Article  PubMed  CAS  Google Scholar 

  17. Arnaout, M., Wang, E., Clark, S. and Sieff, C. (1986) Human recombinant granulocyte-macrophage colony-stimulating factor increases cell to cell adhesion and surface expression of adhesion promoting glycoproteins on mature granulocytes.J. Clin. Invest. 78, 597.

    Article  PubMed  CAS  Google Scholar 

  18. Morrissey, P., Bressler, L., Park, L., Alpert, A. and Gillis, S. (1987) Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen presenting cells.J. Immunol. 139, 1113.

    PubMed  CAS  Google Scholar 

  19. Vadas, M., Nicola, N. and Metcalf, D. (1983) Activation of antibody dependent cell mediated cytotoxicity of human neutrophils and eosinophils by separate colony stimulating factors.J. Immunol. 130, 795.

    PubMed  CAS  Google Scholar 

  20. Masucci, P., Wersäll, P., Ragnhammar, P. and Mellstedt, H. (1989) Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.Cancer Immunol. Immunother. 29, 288.

    Article  PubMed  CAS  Google Scholar 

  21. Hill, A., Redmond, R, Austin, O., Grace, P. and Bouchier-Hayes, D. (1993) Granulocyte-macrophage colony-stimulating factor inhibits tumor growth.Br. J. Surg. 80, 1543.

    Article  PubMed  CAS  Google Scholar 

  22. Charak, B., Agah, R. and Mazumder, A. (1993) Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation.Blood 81, 3474.

    PubMed  CAS  Google Scholar 

  23. Hooijberg, E., Sein, J. and van den Berg, P. (1995) Eradication of large human B-cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin-2.Cancer Res. 55, 2627.

    PubMed  CAS  Google Scholar 

  24. Cebon, J., Dempsey, P., Fox, R., Kannourakis, G., Bonnern, E.; Burgess, A. and Morstyn, G. (1988) Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay.Blood 72, 1340.

    PubMed  CAS  Google Scholar 

  25. Hovgaard, D., Mortensen, B., Schifter, S. and Nissen, N. (1992) Clinical pharmacokinetic studies of a human hae- mopoietic growth factor, GM-CSF.Eur. J. Invest. 22, 45.

    Article  CAS  Google Scholar 

  26. Wadhwa, M., Bird, C, Fagerberg, J., Gaines-Das, R., Ragnhammar, P. and Mellstedt, H. (1996) Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy.Clin. Exp. Immunol. 104, 351.

    Article  PubMed  CAS  Google Scholar 

  27. Thompson, J.A., Lee, D.J., Kidd, P., Rubin, E., Kaufman, J., Bonnern, E.M. and Fefer, A. (1989) Subcutaneous granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndrome: Toxicity pharmacokinetics and hematological effects.J. Clin. Oncol. 7, 629.

    PubMed  CAS  Google Scholar 

  28. Gribben, J.G., Devereux, S., Thomas, N.S.B., Keim, M., Jones, H.M., Goldstone, A.H. and Linch, D.C. (1990) Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF.Lancet 335, 434.

    Article  PubMed  CAS  Google Scholar 

  29. von Wussow, P., Pralle, H., Hochkeppel, H.-K., Jakschies, D., Sonnen, S., Schmidt, H., Müller-Rosenau, P., Franke, M., Haferlach, T., Zwingers, T., Rapp, U. and Deicher, H. (1991) Effective natural interferon-a therapy in recombinant interferon-Q-resistant patients with hairy cell leukaemia.Blood 78, 38.

    Google Scholar 

  30. Russo, D., Candoni, A., Zuffa, E., Minisini, R., Silvestri, F., Fanin, R., Zaja, F., Martinelli, G., Tura, S., Botta, G. and Baccarani, M. (1996) Neutralizing anti-interferon-a antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (a2a) and lymphoblastoid interferon-a.Br. J. Haematol 94, 300.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology (Radiumhemmet), Karolinska Hospital, S- 171 76, Stockholm, Sweden

    Peter Ragnhammar

  2. Division of Immunbio logy, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, EN6 3QG, Hertfordshire, UK

    Meenu Wadhwa

Authors
  1. Peter Ragnhammar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meenu Wadhwa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ragnhammar, P., Wadhwa, M. Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. Med Oncol 13, 161–166 (1996). https://doi.org/10.1007/BF02990843

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02990843

Keywords

Search

Navigation